> Details

Poveda, Andrés; Floquet, Anne; Ledermann, Jonathan A.; Asher, Rebecca; Penson, Richard T.; Oza, Amit M.; Korach, Jacob; Huzarski, Tomasz; Pignata, Sandro; Friedlander, Michael; Baldoni, Alessandra; Park-Simon, Tjoung-Won; Tamura, Kenji; Sonke, Gabe S.; Lisyanskaya, Alla; Kim, Jae-Hoon; Filho, Elias Abdo; Milenkova, Tsveta; Lowe, Elizabeth S.; Rowe, Phil; Vergote, Ignace; Pujade-Lauraine, Eric

Olaparib Tablets as Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a BRCA1/2 Mutation (SOLO2/ENGOT-Ov21): A Final Analysis of a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Olaparib Tablets as Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a BRCA1/2 Mutation (SOLO2/ENGOT-Ov21): A Final Analysis of a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial
  • Contributor: Poveda, Andrés; Floquet, Anne; Ledermann, Jonathan A.; Asher, Rebecca; Penson, Richard T.; Oza, Amit M.; Korach, Jacob; Huzarski, Tomasz; Pignata, Sandro; Friedlander, Michael; Baldoni, Alessandra; Park-Simon, Tjoung-Won; Tamura, Kenji; Sonke, Gabe S.; Lisyanskaya, Alla; Kim, Jae-Hoon; Filho, Elias Abdo; Milenkova, Tsveta; Lowe, Elizabeth S.; Rowe, Phil; Vergote, Ignace; Pujade-Lauraine, Eric
  • imprint: Ovid Technologies (Wolters Kluwer Health), 2021
  • Published in: Obstetrical & Gynecological Survey
  • Language: English
  • DOI: 10.1097/ogx.0000000000000962
  • ISSN: 1533-9866; 0029-7828
  • Keywords: Obstetrics and Gynecology ; General Medicine
  • Origination:
  • Footnote:
  • Description: <jats:p>(Abstracted from <jats:italic toggle="yes">Lancet Oncol</jats:italic> 2021;22:620–631)</jats:p> <jats:p>The poly (ADP-ribose) polymerase (PARP) inhibitor olaparib is approved as maintenance therapy in newly diagnosed ovarian cancer or in patients with platinum-sensitive, relapsed ovarian cancer regardless of <jats:italic toggle="yes">BRCA1/2</jats:italic> mutation status. The primary analysis of the SOLO2/ENGOT-Ov21 phase 3 trial found a significant improvement in median progression-free survival associated with olaparib treatment compared with placebo in patients with platinum-sensitive, relapsed ovarian cancer and a <jats:italic toggle="yes">BRCA1/2</jats:italic> mutation.</jats:p>